Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes

Drugs of Today

Volumn 43, Issue 1, 2007, Pages 13-25

  Gallwitz, Baptist ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; STREPTOZOCIN DIABETES; WEIGHT GAIN;

ADENOSINE DEAMINASE; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; PYRAZINES; TRIAZOLES;

EID: 33947420172     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.1.1043909     Document Type: Review

References (58)

1. Smyth, S., Heron, A. Diabetes and obesity: The twin epidemics. Nat Med 2006, 12: 75-80.
2. Lindeman, R.D., Romero, L.J., Hundley, R. et al. Prevalences of type 2 diabetes, the insulin resistance syndrome, and coronary heart disease in an elderly, biethnic population. Diabetes Care 1998, 21: 959-66.
3. Abuissa, H., Bel, D.S., O'Keefe, J.H. Jr. Strategies to prevent type 2 diabetes. Curr Med Res Opin 2005, 21: 1107-14.
4. Prentki, M., Nolan, C.J. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006, 116: 1802-12.
5. Holst, J.J. Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006, 49: 253-60.
6. Taylor, R., Magnusson, I., Rothman, D.L. et al. Direct assessment of liver glycogen storage by 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects. J Clin Invest 1996, 97: 126-32.
7. Gallwitz, B. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinol 2006, 31: 133-47.
8. Creutzfeldt, W. The incretin concept today. Diabetologia 1979, 16: 75-85.
9. Nauck, M., Stockmann, F., Ebert, R., Creutzfeldt, W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29: 46-52.
10. Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R., Creutzfeldt, W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91: 301-7.
11. Toft-Nielsen, M.B., Damholt, M.B., Madsbad, S. et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001, 86: 3717-23.
12. Nauck, M.A., Kleine, N., Orskov, C., Holst, J.J., Willms, B., Creutzfeldt, W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36: 741-4.
13. D'Alessio, D., Vahl, T., Prigeon, R. Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. Horm Metab Res 2004, 36: 837-41.
14. Meier, J.J., Gallwitz, B., Salmen, S. et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003, 88: 2719-25.
15. Turton, M.D., O'Shea, D., Gunn, I. et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379: 69-72.
16. Gutzwiller, J.P., Degen, L., Heuss, L., Beglinger, C. Glucagon-like peptide 1 (GLP-1) and eating. Physiol Behav 2004, 82: 17-9.
17. Drucker, D.J. The biology of incretin hormones. Cell Metab 2006, 3: 153-65.
18. Zander, M., Madsbad, S., Madsen, J.L., Holst, J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002, 359: 824-30.
19. Mentlein, R. Dipeptidyl-peptidase IV (CD26) - Role in the inactivation of regulatory peptides. Regul Pept 1999, 85: 9-24.
20. Demuth, H.U., McIntosh, C.H., Pederson, R.A. Type 2 diabetes - therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005, 1751: 33-44.
21. Mentlein, R., Gallwitz, B., Schmidt, W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993, 214: 829-35.
22. Mest, H.J., Mentlein, R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005, 48: 616-20.
23. Deacon, C.F., Nauck, M.A., Meier, J., Hucking, K., Holst, J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000, 85: 3575-81.
24. Deacon, C.F., Johnsen, A.H., Holst, J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80: 952-7.
25. Deacon, C.F., Nauck, M.A., Toft-Nielsen, M., Pridal, L., Willms, B., Holst, J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44: 1126-31.
26. Knudsen, L.B., Pridal, L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996, 318: 429-35.
27. Meier, J.J., Gethmann, A., Nauck, M.A. et al. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab 2006, 290: E1118-23.
28. Bray, G.M. Exenatide. Am J Health Syst Pharm 2006, 63: 411-8.
29. Nauck, M.A., El-Ouaghlidi, A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 2005, 48: 608-11.
30. Kim, D., Wang, L., Beconi, M. etal. (2R)-4-oxo-4-[3-(trifluoromethyl)- 5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48: 141-51.
31. Bergman, A.J., Stevens, C., Zhou, Y. et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor : A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006, 28: 55-72.
32. Narita, H., Nonaka, K., Stevens, C. et al. Multiple dose administration of sitagliptin, a dipeptidyl peptide IV (DPP-4) inhibitor, in healthy japanese subjects. Diabetes 2006, 55 (Suppl. 1): A127.
33. Miller, S., St. Onge, E.L. Sitagliptin: A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 2006, 40: 1336-43.
34. Nonaka, K., Kakikawa, T., Sato, A. et al. Efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-IV (DPP-4) inhibitor, in Japanese patients with T2DM. Diabetes 2006, 55 (Suppl. 1): A 128.
35. Mest, H.J. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement. Curr Opin Investig Drugs 2006, 7: 338-43.
36. Herman, G.A., Stevens, C., Van Dyck, K. et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005, 78: 675-88.
37. Herman, G.A., Bergmann, J., Wagner, J.A. Sitagliptin, a DPP-4 inhibitor: An overview of the pharmacokinetic (PK) profile and the propensity for drug-drug interactions (DDI). Diabetologia 2006, 49 (Suppl. 1): 481.
38. Herman, G.A., Bergman, A., Stevens, C. et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91: 4612-9.
39. Mistry, G., Bergmann, A., Luo, W.L. et al. Effects of sitagliptin on the pharmacokinetics (PK) of rosiglitazone in healthy subjects. Diabetes 2006, 55 (Suppl. 1): A 463.
40. Ruddy, M.K., Bergmann, A.J., Zheng, W. et al. Sitagliptin, a DPP-4 inhibitor, does not inhibit the pharmacokinetics of the sulfonylurea, glyburide. Diabetes 2006, 55 (Suppl. 1): A 133.
41. Mu, J., Woods, J., Zhou, Y.P. et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic {beta}-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55: 1695-1704.
42. Mu, J., Zhou, Y.P., Woods, J. et al. Direct comparison of efficacy and durability of DPP-4 inhibitor, PPARG agonist and sulfonylurea on glycemic control and beta-cell function in a rodent model of type 2 diabetes. Diabetes 2006, 55 (Suppl. 1): A 140.
43. DeFronzo, R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131: 281-303.
44. Pospisilik, J.A., Martin, J., Doty, T. et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003, 52: 741-50.
45. Pospisilik, J.A., Stafford, S.G., Demuth, H.U. et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002, 51: 943-50.
46. Marguet, D., Baggio, L., Kobayashi, T. et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000, 97: 6874-9.
47. Conarello, S.L., Li, Z., Ronan, J. et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003, 100: 6825-30.
48. Trumper, A., Trumper, K., Horsch, D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 2002, 174: 233-46.
49. Hansotia, T., Drucker, D.J. GIP and GLP-1 as incretin hormones: Lessons from single and double incretin receptor knockout mice. Regul Pept 2005, 128: 125-34.
50. Ahren, B., Hughes, T.E. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology 2005, 146: 2055-9.
51. Aschner, P., Kipnes, M.S., Lunceford, J.K., Sanchez, M., Mickel, C., Williams-Herman, D.E. Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29: 2632-7.
52. Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49: 2564-71.
53. Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G.; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29: 2638-43.
54. Rosenstock, J., Brazg, R., Andryuk, P.J., Lu, K., Stein, P.; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006, 28: 1556-68.
55. Scott, R., Hartley, P., Luo, E. et al. Use of sitagliptin in patients with type 2 diabetes (T2DM) and renal Insufficiency (RI). Diabetes 2006, 55 (Suppl. 1): A 462.
56. Xu, L., Man, C.D., Cobelli, C. et al. Sitagliptin improved beta-cell function in patients with type 2 diabetes (T2DM): A model-based analysis. Diabetes 2006, 55 (Suppl. 1): A 466.
57. Ahren, B. What mediates the benefits associated with dipeptidyl peptidase-IV inhibition? Diabetologia 2005, 48: 605-7.
58. Nielsen, L.L. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 2005, 10: 703-10.